Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Adaptimmune
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Adaptimmune
-
On
#WorldCancerDay
the @WHO issued this report (https://bit.ly/2vb3Cs7 ). Prevention and management are key - especially for rarer#cancer indications such as#sarcoma. Our teams work hard to discover and develop new#celltherapy treatments.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It is
#WorldCancerDay
- This word cloud summarizes key words from the #IAmAndIWill
statements shared by colleagues in our company. We are committed to developing innovative cell therapies aiming to transform the lives of people with #cancer.@uicc#celltherapypic.twitter.com/K7gAtqMAYZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A key topic today at
@myESMO#sarcoma & GIST symposium has been the importance of network for rare#cancer communities. A Trama@IstTumori praises the referral#network in#France allowing exchange between physicians. This is why we are here meeting physicians & patient groups.pic.twitter.com/zD145TcTZ1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Adaptimmune proslijedio/la je Tweet
We are stronger when we work together:
#sarcoma patients, clinicians, researchers, scientists, and advocates. An entire session facilitating our common goals@myESMO#GIST#advocacypic.twitter.com/NM7j2eIt45
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#cancer cells may cause CAR T-cell resistance (@CD_AACR article: https://bit.ly/38X6IP4 ). This may create even more of a challenge for solid tumors. We saw high PD1 levels in a non-responder with ADP-A2M4 and we are working on a combination trial with a PD1 checkpoint inhibitor.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"Next week, we will be meeting with some of our SPEARHEAD-1 investigators, as well as patient groups and other partners, during the
@myESMO#sarcoma & GIST symposium. Let us know if you would want to meet.#cancer#celltherapy"pic.twitter.com/3F6OvNGXRo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are committed to delivering new therapies to people with synovial
#sarcoma. There is still a high unmet medical need for treatment of this#cancer and we are recruiting patients in our Phase 2 SPEARHEAD-1#clinicaltrial now (https://bit.ly/36ryTnI ).#oncologypic.twitter.com/mybeX4jAcbHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out this article (https://bit.ly/2GkXWhS ) by
@bvantine1 in@OncologyTimes talking about the powerful potential of ADP-A2M4 to help#patients with synovial#sarcoma#cancer. Our Phase 2 SPEARHEAD-1#clinicaltrial is enrolling now - click below to learn more.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We opened our first EU
#clinicaltrial site in#Spain, enrolling patients w/ synovial#sarcoma & MRCLS in the Phase 2 trial SPEARHEAD-1. We will open more sites in Spain, as well as#France and#UK. Check out this video in Spanish on how SPEAR T-cells work.https://bit.ly/2TRyWqqHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our
#JPM2020 updates did not include our Phase 2 SPEARHEAD-1#clinicaltrial for patients with synovial#sarcoma and MRCLS. We are progressing well and the trial is open at ~20 sites in US & Spain, with sites in UK and France opening soon. Click below to learn more.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Following
#JPM2020, our team is reflecting on all the exhilarating#immunotherapy announcements that we made over the past few days. If you missed our news, you can find the full press releases here: https://bit.ly/2uyaGix pic.twitter.com/kQzwPJ5GsE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
On Monday, we announced that we have seen partial responses in 4 additional solid tumor indications – beyond the responses already observed in synovial
#sarcoma. Read the press release here: https://bit.ly/2tXRo5Q#JPM2020$ADAPpic.twitter.com/3sc5CFqQQs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#JPM2020 Recap: we shared three exciting announcements regarding responses in multiple#cancers, a partnership with@AstellasUS, and appointment of our CMO. Learn more here in our news section: https://bit.ly/2uyaGix pic.twitter.com/JUfFIPMIS8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NEWS: Today, we announced a partnership with
@AstellasUS to bring new stem-cell derived allogeneic T-cell therapies to#cancer patients. Read the details of the deal here: https://bit.ly/2uF7lxU#JPM2020pic.twitter.com/hjHjZD1yKI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We have an exciting leadership update! Dr. Elliot Norry has been appointed as Chief Medical Officer. After being with
$ADAP for the past 4 years, we could not be more grateful that he will continue to be part of our team. Read more here: https://bit.ly/30i0vdA#JPM2020pic.twitter.com/mf7Qh5z5eb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NEWS: We are thrilled to share with the
#cancer community that we have seen partial responses in 4 additional solid tumor indications – beyond the responses already observed in synovial#sarcoma! Read the press release here: https://bit.ly/2QMUpi7#JPM2020$ADAPpic.twitter.com/2FDOssbvfs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are recruiting
#patients for our SURPASS#clinicaltrial in#Philadelphia,#Oklahoma, &#Boston at@TJUHospital,@OUMedicine, and@MassGeneralNews. We are looking for patients with multiple#tumor indications - click below to learn more.#oncologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out this article in
@OncLive featuring@bvantine1 of@WUSTLmed discussing our ADP-A2M4#celltherapy in synovial#sarcoma and how it is a "game changer" for#patients with this deadly#cancer. Click below to read the full article.#oncologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We hope everyone had a good holiday season. We are back to work to deliver
#celltherapy for patients with#cancer. Reach out to meet with management or to schedule an interview at#JPM2020: https://bit.ly/2qNoeF5 pic.twitter.com/C9T8ndpLiH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.